Lawrence Hineline J.'s most recent trade in Intra-Cellular Therapies Inc was a trade of 6,618 Common Stock done at an average price of $66.9 . Disclosure was reported to the exchange on March 7, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.93 per share. | 07 Mar 2024 | 6,618 | 0 (0%) | 0% | 66.9 | 442,943 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.26 per share. | 07 Mar 2024 | 6,514 | 6,618 (0%) | 0% | 66.3 | 431,618 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 5,582 | 5,582 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 5,582 | 5,582 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.73 per share. | 07 Mar 2024 | 4,539 | 4,539 (0%) | 0% | 56.7 | 257,497 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 4,539 | 4,539 | - | - | Stock Option (right to purchase) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.47 per share. | 07 Mar 2024 | 4,475 | 64 (0%) | 0% | 66.5 | 297,453 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 65.28 per share. | 07 Mar 2024 | 4,453 | 1,129 (0%) | 0% | 65.3 | 290,692 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.54 per share. | 07 Mar 2024 | 1,100 | 29 (0%) | 0% | 66.5 | 73,194 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.12 per share. | 07 Mar 2024 | 64 | 0 (0%) | 0% | 67.1 | 4,296 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.31 per share. | 07 Mar 2024 | 29 | 0 (0%) | 0% | 67.3 | 1,952 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 26,266 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 13,132 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 26,227 | 26,227 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,455 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Hineline J. Lawrence | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,455 | 7,455 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence Hineline J. | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.38 per share. | 23 Feb 2024 | 6,867 | 288 (0%) | 0% | 69.4 | 476,432 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 5,882 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | J. Hineline Lawrence | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 23 Feb 2024 | 5,882 | 5,882 (0%) | 0% | 36.9 | 216,987 | Common Stock |
| IntraCellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.47 per share. | 23 Feb 2024 | 5,282 | 600 (0%) | 0% | 69.5 | 366,941 | Common Stock |
| IntraCellular Therapies Inc | Hineline J. Lawrence | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.81 per share. | 23 Feb 2024 | 600 | 0 (0%) | 0% | 69.8 | 41,886 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 68.33 per share. | 23 Feb 2024 | 300 | 7,155 (0%) | 0% | 68.3 | 20,499 | Common Stock |
| IntraCellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 23 Feb 2024 | 288 | 0 (0%) | 0% | 70.1 | 20,203 | Common Stock |
| IntraCellular Therapies Inc | Lawrence Hineline J. | SVP of Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 11,183 | 11,183 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.61 per share. | 01 Feb 2024 | 10,998 | 185 (0%) | 0% | 66.6 | 732,577 | Common Stock |
| IntraCellular Therapies Inc | J. Hineline Lawrence | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 01 Feb 2024 | 185 | 0 (0%) | 0% | 67.4 | 12,460 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 64.37 per share. | 14 Jun 2023 | 44,035 | 3,592 (0%) | 0% | 64.4 | 2,834,533 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 40,472 | 0 | - | - | Stock Option (right to purchase) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.63 per share. | 14 Jun 2023 | 40,472 | 40,472 (0%) | 0% | 53.6 | 2,170,513 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 63.35 per share. | 14 Jun 2023 | 34,227 | 47,627 (0%) | 0% | 63.3 | 2,168,280 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 25,082 | 0 | - | - | Stock Option (right to purchase) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.94 per share. | 14 Jun 2023 | 25,082 | 65,554 (0%) | 0% | 23.9 | 600,463 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 11,762 | 5,882 | - | - | Stock Option (right to purchase) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 14 Jun 2023 | 11,762 | 77,316 (0%) | 0% | 36.9 | 433,900 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 4,538 | 9,078 | - | - | Stock Option (right to purchase) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.73 per share. | 14 Jun 2023 | 4,538 | 81,854 (0%) | 0% | 56.7 | 257,441 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 65.01 per share. | 14 Jun 2023 | 3,592 | 0 (0%) | 0% | 65.0 | 233,516 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 15,663 | 15,663 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 43.17 per share. | 09 Mar 2023 | 12,963 | 2,700 (0%) | 0% | 43.2 | 559,613 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 5,582 | 11,164 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 5,582 | 5,582 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.97 per share. | 09 Mar 2023 | 5,324 | 258 (0%) | 0% | 45.0 | 239,420 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 09 Mar 2023 | 2,700 | 0 (0%) | 0% | 42.5 | 114,804 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.14 per share. | 09 Mar 2023 | 258 | 0 (0%) | 0% | 44.1 | 11,388 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 39,398 | 39,398 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,455 | 7,455 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.03 per share. | 23 Feb 2023 | 7,455 | 0 (0%) | 0% | 47.0 | 350,609 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,455 | 7,455 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 18 Feb 2023 | 53,968 | 53,968 (0%) | 0% | 12.7 | 687,013 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 53,968 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 49.81 per share. | 18 Feb 2023 | 52,279 | 1,689 (0%) | 0% | 49.8 | 2,604,017 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,443 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,443 | 10,443 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 46.54 per share. | 18 Feb 2023 | 8,649 | 1,794 (0%) | 0% | 46.5 | 402,524 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 50.59 per share. | 18 Feb 2023 | 1,689 | 0 (0%) | 0% | 50.6 | 85,447 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 48.72 per share. | 18 Feb 2023 | 900 | 94 (0%) | 0% | 48.7 | 43,848 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.32 per share. | 18 Feb 2023 | 800 | 994 (0%) | 0% | 47.3 | 37,856 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 49.60 per share. | 18 Feb 2023 | 94 | 0 (0%) | 0% | 49.6 | 4,662 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 16,746 | 16,746 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 13,616 | 13,616 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 10,443 | 10,443 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 10,443 | 10,443 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 55.72 per share. | 18 Feb 2022 | 5,816 | 4,627 (0%) | 0% | 55.7 | 324,068 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 54.99 per share. | 18 Feb 2022 | 4,627 | 0 (0%) | 0% | 55.0 | 254,439 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 19,639 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 40.77 per share. | 08 Jan 2022 | 12,434 | 4,100 (0%) | 0% | 40.8 | 506,934 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 40.07 per share. | 08 Jan 2022 | 4,100 | 0 (0%) | 0% | 40.1 | 164,287 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 41.61 per share. | 08 Jan 2022 | 3,105 | 16,534 (0%) | 0% | 41.6 | 129,199 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.84 per share. | 21 Dec 2021 | 100,803 | 48,735 (0%) | 0% | 47.8 | 4,822,416 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Dec 2021 | 72,120 | 122,120 (0%) | 0% | 17.6 | 1,267,148 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 72,120 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 52,880 | 10,837 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.73 per share. | 21 Dec 2021 | 52,880 | 175,000 (0%) | 0% | 15.7 | 831,802 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 21 Dec 2021 | 50,000 | 50,000 (0%) | 0% | 16.9 | 843,000 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 21 Dec 2021 | 35,135 | 13,600 (0%) | 0% | 46.9 | 1,648,183 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 48.67 per share. | 21 Dec 2021 | 25,462 | 149,538 (0%) | 0% | 48.7 | 1,239,236 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 45.81 per share. | 21 Dec 2021 | 9,200 | 4,400 (0%) | 0% | 45.8 | 421,452 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.95 per share. | 21 Dec 2021 | 3,800 | 600 (0%) | 0% | 45.0 | 170,810 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.28 per share. | 21 Dec 2021 | 600 | 0 (0%) | 0% | 44.3 | 26,568 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 22,364 | 22,364 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 17,644 | 17,644 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 10,442 | 20,886 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 10,442 | 10,442 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 39.27 per share. | 18 Feb 2021 | 9,242 | 1,200 (0%) | 0% | 39.3 | 362,933 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 38.91 per share. | 18 Feb 2021 | 1,200 | 0 (0%) | 0% | 38.9 | 46,692 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,638 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,639 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 08 Jan 2021 | 17,262 | 2,376 (0%) | 0% | 32.1 | 553,592 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 31.64 per share. | 08 Jan 2021 | 2,376 | 0 (0%) | 0% | 31.6 | 75,177 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2021 | 350 | 0 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 16,160 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 03 Jan 2021 | 12,710 | 3,450 (0%) | 0% | 31.4 | 399,094 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 30.94 per share. | 03 Jan 2021 | 3,100 | 350 (0%) | 0% | 30.9 | 95,914 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 11 Nov 2020 | 28,034 | 0 (0%) | 0% | 25.4 | 712,344 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 11 Nov 2020 | 10,000 | 28,034 (0%) | 0% | 3.3 | 32,600 | Common Stock |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.84 per share. | 11 Nov 2020 | 10,000 | 18,034 (0%) | 0% | 2.8 | 28,400 | Common Stock |